Exact Sciences Reveals Oncodetect MRD Test Results in Major TNBC Study
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 11 2025
0mins
Source: Newsfilter
- Significant Prognostic Performance: In the NSABP B-59 substudy, the Oncodetect test demonstrated that post-surgical MRD-positive patients had approximately a 30-fold higher risk of distant recurrence compared to MRD-negative patients, underscoring the test's importance in early triple-negative breast cancer (TNBC).
- Clinical Data Support: The study analyzed 147 patients, revealing a strong association between post-surgery ctDNA detection and distant recurrence risk, with 95% of MRD-negative patients remaining free of distant recurrence at three years, highlighting the prognostic value of ctDNA detection.
- Guiding Treatment Decisions: By identifying patients at high risk for recurrence, the Oncodetect test aids in optimizing post-surgical treatment decisions, potentially improving patient survival rates and treatment outcomes, thus advancing personalized medicine.
- Future Research Plans: Exact Sciences intends to submit these findings to a peer-reviewed journal and to MolDx for Medicare coverage support, demonstrating the company's ongoing investment and commitment in the breast cancer diagnostics field.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
